Results 171 to 180 of about 36,008 (205)
Some of the next articles are maybe not open access.
Drugs & Aging, 1998
Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease. While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine ...
H P, Volz, C H, Gleiter
openaire +2 more sources
Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease. While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine ...
H P, Volz, C H, Gleiter
openaire +2 more sources
Monoamine oxidase A and B inhibitors
Expert Opinion on Therapeutic Patents, 1998This patent update relates to monoamine oxidase inhibitors, covers the patent activity in this field for the last 3 - 5 years and focuses on the most relevant filings. Patents are classified according to the type of MAO inhibition: selective MAO-A and MAO-B inhibitors, and mixed and reversible MAO-A and MAO-B inhibitors.
Samir Jegham, Pascal George
openaire +1 more source
Process characterization of a monoamine oxidase
Journal of Molecular Catalysis B: Enzymatic, 2014Abstract Redox biocatalysis is currently gaining focus because it offers exquisite selectivity using mild oxidants, such as oxygen (which is environmentally benign). However, it is often challenging to implement oxidative reactions at scale due to the low activity and stability of the biocatalyst under industrial conditions.
Hemalata Ramesh, John M. Woodley
openaire +1 more source
Monoamine Oxidase Inhibitors: A Clinical Colloquy
Psychiatric Annals, 2014A knowledgeable, experienced group of experts, willing to disagree, discuss the rationale and practice of monoamine oxidase inhibitor (MAOI) therapy. The goal is to provide a discussion pertinent to clinical practice. The moderator offered participation to researchers and clinicians highly experienced in MAOI therapy.
Edward H. Tobe +4 more
openaire +1 more source
A new specific inhibitor of monoamine oxidase A
Biochemical Pharmacology, 1982A new propynylamine has been tested as an inhibitor of MAO. Loosely based upon the structure of clorgyline, it is an irreversible inhibitor of MAO A but is apparently indifferent towards MAO B. This compound, N1-(2,4-dinitrophenyl)-N2-prop-2-ynyl 1,3-diaminopropane, may be useful as a model for the design of more potent but equally specific inhibitors ...
openaire +2 more sources
Monoamine oxidase inhibitors: a review.
The Journal of clinical psychiatry, 1983Current knowledge about monoamine oxidase (MAO) inhibitors is reviewed, with particular attention to the mode of action, prognostic indicators, treatment protocol, response prediction, toxicity, and untoward drug interactions. The MAO inhibitors are often effective in the treatment of affective disorders, anxiety states, and phobias.
openaire +1 more source
Monoamine Oxidase Inhibitors: A New Generation
Psychopharmacology BulletinMonoamine oxidase inhibitors (MAOIs), which ushered in the modern era of psychopharmacology in the 1950s, have remained useful in the treatment of depression despite important safety concerns, such as acute hypertensive episodes brought on by ingestion of foods with high-tyramine content.
Donald S. Robinson, null MD
openaire +1 more source
Oxidase reactions in photoredox catalysis
Chemical Society Reviews, 2021Nicholas L Reed, Tehshik P Yoon
exaly
Adafenoxate: A monoamine oxidase and biogenic monoamine uptake inhibitor
Pharmacological Research, 1995S.L. Stancheva, L.G. Alova
openaire +1 more source
A monoamine oxidase inhibitor in human urine
Biochemical Pharmacology, 1980V, Glover, M A, Reveley, M, Sandler
openaire +2 more sources